💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Trimethobenzamide

CHEMBL1201256 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
388.5 g/mol
LogP
2.3
Phase
4

Trimethobenzamide is an antiemetic agent that acts centrally by blocking dopamine receptors in the chemoreceptor trigger zone of the medulla, thereby suppressing nausea and vomiting. It is used to treat nausea and vomiting associated with various conditions including postoperative states and gastroenteritis, and is sometimes used as adjunctive therapy in Parkinson's disease patients experiencing drug-related nausea. Unlike phenothiazine antiemetics, it has a relatively low risk of extrapyramidal side effects.

आणविक भार

388.5000 g/mol

LogP

2.30

TPSA

69.30 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

पार्किंसन रोग

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC

                

                

                
                

                    
InChI

                    
InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H28N2O5

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
घूर्णनीय बंधन

                        
10

                    

                    
                    
                    

                        
भारी परमाणु

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
Trimethobenzamide is an antiemetic agent that acts centrally by blocking dopamine receptors in the chemoreceptor trigger zone of the medulla, thereby suppressing nausea and vomiting. It is used to treat nausea and vomiting associated with various conditions including postoperative states and gastroenteritis, and is sometimes used as adjunctive therapy in Parkinson's disease patients experiencing drug-related nausea. Unlike phenothiazine antiemetics, it has a relatively low risk of extrapyramidal side effects.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Trimethobenzamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201256.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5577.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.